1,https://www.reuters.com/article/brief-west-pharmaceutical-services-to-jo/brief-west-pharmaceutical-services-to-join-sp-500-index-idUSFWN2D304F,2020-05-21T10:13:18Z,BRIEF-West Pharmaceutical Services To Join S&P 500 Index,May 21 (Reuters) - West Pharmaceutical Services Inc:,"* WEST PHARMACEUTICAL SERVICES, INC. TO JOIN S&P 500 INDEX Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)"
2,https://www.reuters.com/article/brief-west-pharmaceutical-services-says/brief-west-pharmaceutical-services-says-q1-adjusted-earnings-per-share-1-01-idUSASA00LLX,2020-04-23T10:03:32Z,BRIEF-West Pharmaceutical Services Says Q1 Adjusted Earnings Per Share $1.01,April 23 (Reuters) - West Pharmaceutical Services Inc :,* Q1 EARNINGS PER SHARE ESTIMATE $0.82 -- REFINITIV IBES DATA,* Q1 SALES $491.5 MILLION VERSUS REFINITIV IBES ESTIMATE OF $466.8 MILLION,"* FY2020 EARNINGS PER SHARE VIEW $3.39, REVENUE VIEW $1.94 BILLION -- REFINITIV IBES DATA",* ORGANIC SALES GROWTH IS EXPECTED TO BE APPROXIMATELY 8% IN 2020,* NET SALES GUIDANCE INCLUDES AN ESTIMATED FULL-YEAR HEADWIND OF $26 MILLION FOR FULL-YEAR 2020 Source text for Eikon: Further company coverage:
3,https://www.reuters.com/article/brief-west-elects-new-director-robert-fr/brief-west-elects-new-director-robert-friel-to-board-idUSASA00DNW,2020-02-17T13:16:27Z,"BRIEF-West Elects New Director, Robert Friel, To Board",Feb 17 (Reuters) - West Pharmaceutical Services Inc:,* WEST PHARMACEUTICAL SERVICES - BOARD HAS ELECTED ROBERT FRIEL AS ITS NEWEST MEMBER,"* WEST PHARMACEUTICAL SERVICES - WITH ADDITION OF FRIEL, WESTâ€™S BOARD INCREASES IN SIZE TO 11 DIRECTORS Source text for Eikon: Further company coverage:"
4,https://www.reuters.com/article/brief-west-announces-q4-earnings-per-sha/brief-west-announces-q4-earnings-per-share-0-84-idUSASA00D95,2020-02-13T11:34:53Z,BRIEF-West Announces Q4 Earnings Per Share $0.84,Feb 13 (Reuters) - West Pharmaceutical Services Inc:,* Q4 EARNINGS PER SHARE ESTIMATE $0.72 -- REFINITIV IBES DATA,* Q4 SALES $470.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $451.5 MILLION,* SEES 2020 ORGANIC SALES GROWTH IS EXPECTED TO BE IN RANGE OF 7% TO 8%,* FULL-YEAR 2020 CAPITAL SPENDING IS EXPECTED TO BE APPROXIMATELY 7% OF EXPECTED FULL-YEAR 2020 NET SALES,* WEST PHARMACEUTICAL SERVICES - NET SALES GUIDANCE INCLUDES ESTIMATED HEADWIND OF $15 MILLION FOR FULL-YEAR 2020 BASED ON CURRENT FOREIGN EXCHANGE RATES,* FY2020 EARNINGS PER SHARE VIEW $3.46 -- REFINITIV IBES DATA Source text for Eikon: Further company coverage:
5,https://www.reuters.com/article/brief-west-announces-board-approved-q4-d/brief-west-announces-board-approved-q4-dividend-of-0-15-share-idUSASC09ZE4,2018-05-03T10:19:54Z,BRIEF-West Announces Board Approved Q4 Dividend Of $0.15/Share,May 3 (Reuters) - West Pharmaceutical Services Inc:,"* WEST ANNOUNCES THIRD-QUARTER DIVIDEND, INCREASE TO FOURTH-QUARTER DIVIDEND AND PARTICIPATION IN UPCOMING INVESTOR CONFERENCES","* WEST PHARMACEUTICAL SERVICES - BOARD APPROVED Q4 DIVIDEND OF $0.15/SHARE, UP 7.1% OVER $0.14 PER SHARE DECLARED FOR EACH OF FOUR PRECEDING QUARTERS Source text for Eikon: Further company coverage:"
6,https://www.reuters.com/article/brief-west-announces-q1-earnings-per-sha/brief-west-announces-q1-earnings-per-share-0-58-idUSASC09XLU,2018-04-26T10:13:26Z,BRIEF-West Announces Q1 Earnings Per Share $0.58,April 26 (Reuters) - West Pharmaceutical Services Inc :,* Q1 SALES $415.7 MILLION VERSUS I/B/E/S VIEW $404.2 MILLION,* Q1 EARNINGS PER SHARE VIEW $0.64 -- THOMSON REUTERS I/B/E/S,"* FY2018 EARNINGS PER SHARE VIEW $2.82, REVENUE VIEW $1.72 BILLION -- THOMSON REUTERS I/B/E/S",* ESTIMATES ITS 2018 CAPITAL SPENDING WILL BE LESS THAN $150 MILLION,* WEST PHARMACEUTICAL SERVICES - CUMULATIVE EFFECT OF NEW ACCOUNTING RULES HAD IMMATERIAL NEGATIVE IMPACT TO Q1 2018 NET SALES OF $3 MILLION Source text for Eikon: Further company coverage:
